White blood cell disorders:

Recent Updates:

Monograph added.

Indications for NYVEPRIA:

To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.

Limitations of Use:

Not for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Adults and Children:

See full labeling. ≥45kg: Do not give between 14 days before and 24 hours after chemotherapy. 6mg SC once per chemotherapy cycle. Children (<10kg): 0.1mg/kg; (10–20kg): 1.5mg; (21–30kg): 2.5mg; (31–44kg): 4mg. Direct administration of prefilled syringe with doses <6mg is not recommended.

NYVEPRIA Warnings/Precautions:

Monitor for splenomegaly, splenic rupture, acute respiratory distress syndrome (ARDS); evaluate if fever, lung infiltrates, or respiratory distress occurs; discontinue if ARDS diagnosed. Permanently discontinue if serious allergic reactions develop. Sickle cell disorders; discontinue if sickle cell crisis occurs. Monitor for glomerulonephritis; consider dose reduction or interruption if treatment-related. Monitor CBC during therapy. Discontinue if aortitis is suspected. Myeloid malignancies. Myelodysplasia. Possible transient (+) bone imaging changes in nuclear imaging. Pregnancy. Nursing mothers.

NYVEPRIA Classification:

Granulocyte colony stimulating factor.

Adverse Reactions:

Bone or extremity pain; anaphylaxis, ARDS, splenic rupture, glomerulonephritis, leukocytosis, aortitis, capillary leak syndrome (monitor closely if occurs).

Generic Drug Availability:

NO

How Supplied:

Single-dose prefilled syringe—1 (w. supplies)

Pricing for NYVEPRIA

6mg/0.6ml syringe (Qty: 5)
Appx. price $20027
GoodRx